As program director studying the clinical immunology of diabetes, I oversee a variety of research projects designed to improve treatment of this disease. My responsibilities include directing the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) program—which supports innovative research by small businesses that have the potential for commercialization—in areas related to immunology and diabetes. These areas include: drug discovery for diabetes and other endocrine diseases; new technologies for islet isolation, stem cell/regeneration, and transplantation; immune modulatory agents for the primary and secondary prevention of diabetes; inflammatory aspects of type 2 diabetes, insulin resistance, and obesity; and closed-loop systems/artificial pancreas development. I oversee research on glucose sensors and drug development and serve as co-director of the Rapid Access to Intervention Development program, a cooperative effort to facilitate translation of new and promising therapies. My duties also include acting as the executive secretary of the Clinical Islet Transplantation Consortium Data and Safety Monitoring Board, and I represent the NIDDK on several trans-NIH working groups on metabolic monitoring, inflammatory processes, and autoimmunity.